PD-1 inhibitors (e.g., nivolumab, pembrolizumab) and PD-L1 inhibitors (e.g., atezolizumab, avelumab, durvalumab) followed and the spectrum of indications has widened to different tumors, including, for instance, non-small cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin lymphoma, head and neck squamous cell cancer, hepatocellular carcinoma [2–9]. Here, PDCD1 is linked to non-small cell lung carcinoma.